NCT03212586 - BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

May 3, 2018

Study Completion Date

July 27, 2018

Conditions

Clinical Trials, Phase I as Topic

Interventions

DRUG

BAY1902607

Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)

DRUG

Placebo

Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)

Trial Locations (1)

13353

CRS Clinical Research Services Berlin GmbH, Berlin